Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

“The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”

View ORCID ProfilePascal Johann, Dominic Lenz, Markus Ries
doi: https://doi.org/10.1101/2021.01.01.21249120
Pascal Johann
1German Cancer Research Center (DKFZ), Division of Pediatric Neurooncology, 69120 Heidelberg, Germany
2Paediatric and Adolescent Medicine, Swabian Children’s Cancer Center Augsburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pascal Johann
  • For correspondence: p.johann@kitz-heidelberg.de
Dominic Lenz
3Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Ries
3Pediatric Neurology and Metabolic Medicine, Center for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
4Center for Rare Disorders, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Glioblastoma multiforme (GBM) is the most common malignant brain tumor among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing rapidly. However, the clinical outcomes in GBM patients with currently available therapies are still dismal. An insight into the current drug development pipeline for GBM is therefore of particular interest.

Objectives To provide a quantitative clinical-regulatory insight into the status of FDA orphan drug designations for compounds intended to treat GBM.

Methods Quantitative cross-sectional analysis of the U.S. Food and Drug Administration Orphan Drug Product database between 1983 and 2020. STROBE criteria were respected.

Results Four orphan drugs out of 161 (2,4%) orphan drug designations were approved for the treatment for GBM by the FDA between 1983 and 2020. Fourteen orphan drug designations were subsequently withdrawn for unknown reasons. The number of orphan drug designations per year shows a growing trend. In the last decade, the therapeutic mechanism of action of designated compounds intended to treat glioblastoma shifted from cytotoxic drugs (median year of designation 2008) to immunotherapeutic approaches and small molecules (median year of designation 2014 and 2015 respectively) suggesting an increased focus on precision in the therapeutic mechanism of action for compounds the development pipeline.

Conclusion Despite the fact that current pharmacological treatment options in GBM are sparse, the drug development pipeline is steadily growing. In particular, the surge of designated immunotherapies detected in the last years raises the hope that elaborate combination possibilities between classical therapeutic backbones (radiotherapy) and novel, currently experimental therapeutics may help to provide better therapies for this deadly disease in the future.

Strengths and limitations

  • This study provides a quantitative overview on the drug development pipeline for pediatric and adult oncology in general and specifically for the indication glioblastoma

  • Analyzing the therapeutic mechanisms of designated compounds in glioblastoma reveals an increased focus on personalized and targeted therapies

  • The precise reasons for failure of approved drugs and for withdrawal of approved drugs in glioblastoms are unknown

  • For the analysis, only the databases “FDALabel” (https://nctr-crs.fda.gov/fdalabel/ui/search) and the FDA Orphan drug product designation database (https://www.accessdata.fda.gov/scripts/opdlisting/oopd/) were considered

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research received no specific grant from any funding agency in the public, commercial or non-profit sectors.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University Hospital Heidelberg

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data relevant to the study are included in the article or uploaded as supplementary infor-mation. All data relevant to the study are included in the article.

  • Abbreviations

    ALL
    Acute lymphoblastic leukemia
    AML
    Acute myeloid leukemia
    CAR
    Chimeric antigen receptor
    CLL
    Chronic lymphocytic leukemia
    EGFR
    Epidermal growth factor receptor
    FDA
    Food and drug administration
    GBM
    Glioblastoma
    GIST
    Gastrointestinal stroma tumor
    GVH
    Graft versus host disease
    HCC
    Hepatocellular carcinoma
    HL
    Hemophagocytic lymphhistiocytosis
    MB
    Medulloblastoma
    MDS
    Myelodysplastic syndrome
    MGMT
    Methylguaninmethyltransferase
    MPN
    Myeloproliferative neoplasia
    NC
    Nasopharyngeal carcinoma
    NTRK
    Neurotrophic tyrosine kinase
    PNH
    Paroxysmal nightly heomglobinuria
    SCD
    Sickle cell disease
    VEGF
    Vasoendothelial growth factor
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted January 04, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    “The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    “The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”
    Pascal Johann, Dominic Lenz, Markus Ries
    medRxiv 2021.01.01.21249120; doi: https://doi.org/10.1101/2021.01.01.21249120
    Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Citation Tools
    “The drug development pipeline for glioblastoma - a cross sectional assessment of the FDA Orphan Drug Product designation database”
    Pascal Johann, Dominic Lenz, Markus Ries
    medRxiv 2021.01.01.21249120; doi: https://doi.org/10.1101/2021.01.01.21249120

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (62)
    • Allergy and Immunology (142)
    • Anesthesia (44)
    • Cardiovascular Medicine (408)
    • Dentistry and Oral Medicine (67)
    • Dermatology (47)
    • Emergency Medicine (141)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
    • Epidemiology (4813)
    • Forensic Medicine (3)
    • Gastroenterology (177)
    • Genetic and Genomic Medicine (671)
    • Geriatric Medicine (70)
    • Health Economics (187)
    • Health Informatics (621)
    • Health Policy (314)
    • Health Systems and Quality Improvement (200)
    • Hematology (85)
    • HIV/AIDS (155)
    • Infectious Diseases (except HIV/AIDS) (5281)
    • Intensive Care and Critical Care Medicine (326)
    • Medical Education (91)
    • Medical Ethics (24)
    • Nephrology (73)
    • Neurology (677)
    • Nursing (41)
    • Nutrition (111)
    • Obstetrics and Gynecology (124)
    • Occupational and Environmental Health (203)
    • Oncology (438)
    • Ophthalmology (138)
    • Orthopedics (36)
    • Otolaryngology (88)
    • Pain Medicine (35)
    • Palliative Medicine (15)
    • Pathology (128)
    • Pediatrics (193)
    • Pharmacology and Therapeutics (129)
    • Primary Care Research (84)
    • Psychiatry and Clinical Psychology (768)
    • Public and Global Health (1799)
    • Radiology and Imaging (321)
    • Rehabilitation Medicine and Physical Therapy (138)
    • Respiratory Medicine (255)
    • Rheumatology (86)
    • Sexual and Reproductive Health (69)
    • Sports Medicine (61)
    • Surgery (100)
    • Toxicology (23)
    • Transplantation (28)
    • Urology (37)